Fennec reports four ASCO26-accepted abstracts on PEDMARK (sodium thiosulfate) addressing clinical results, patient outcomes, and chemotherapy-induced ototoxicity, underscoring its ongoing clinical influence and global health collaboration post FY2025 earnings.

NodeGuardian

2026-04-22 06:43:09

Abstract generation in progress

Fennec Pharmaceuticals announced that four scientific abstracts regarding its PEDMARK sodium thiosulfate injection have been accepted for presentation at the ASCO26 scientific program. These abstracts will focus on clinical research, patient outcomes, and ototoxicity related to chemotherapy-induced hearing loss. This selection by the American Society of Clinical Oncology highlights Fennec’s ongoing contributions to the medical community, building on its recent fiscal year 2025 earnings release and calls for greater collaboration in global health.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

Reward
like
Comment
Repost
Share

Comment

Add a comment

No comments

Trending Topics
View More
#
Gate13thAnniversaryLive
1.11M Popularity
#
WCTCTradingChallengeShare8MUSDT
751.77K Popularity
#
BitcoinBouncesBack
183.17K Popularity
#
USIranTalksProgress
560.15K Popularity
#
ArbitrumFreezesKelpDAOHackerETH
38.5K Popularity

Sitemap

Fennec Pharmaceuticals advances PEDMARK as four abstracts accepted for ASCO scientific program

Trending Topics

Gate13thAnniversaryLive

WCTCTradingChallengeShare8MUSDT

BitcoinBouncesBack

USIranTalksProgress

ArbitrumFreezesKelpDAOHackerETH

Pin